Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
Janssen O, Vos SJB, García-Negredo G, Tochel C, Gustavsson A, Smith M, Ly A, Nelson M, Baldwin H, Sudlow C, Bexelius C, Jindra C, Vaci N, Bauermeister S, Gallacher J, Ponjoan A, Dufouil C, Garre Olmo J, Pedersen L, Skoog I, Hottgenroth A, Visser PJ, van der Lei J, Diaz C. Janssen O, et al. Alzheimers Dement. 2020 Mar;16(3):461-471. doi: 10.1016/j.jalz.2019.09.087. Epub 2020 Jan 6. Alzheimers Dement. 2020. PMID: 32157788
What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review.
Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, Nelson M, Bintener C, Fantoni E, Garre-Olmo J, Janssen O, Jindra C, Jørgensen IF, McKeown A, Öztürk B, Ponjoan A, Potashman MH, Reed C, Roncancio-Diaz E, Vos S, Sudlow C; ROADMAP consortium. Tochel C, et al. Among authors: janssen o. Alzheimers Dement (Amst). 2019 Mar 7;11:231-247. doi: 10.1016/j.dadm.2018.12.003. eCollection 2019 Dec. Alzheimers Dement (Amst). 2019. PMID: 30906845 Free PMC article.
Characteristics of subjective cognitive decline associated with amyloid positivity.
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer's Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group; Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Janssen O, et al. Alzheimers Dement. 2022 Oct;18(10):1832-1845. doi: 10.1002/alz.12512. Epub 2021 Dec 8. Alzheimers Dement. 2022. PMID: 34877782 Free PMC article.
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ; Amyloid Biomarker Study Group; Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Chételat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerström M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fröhlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, Gómez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lleó A, Löwenmark M, Madsen K, Maier W, Marcusson J, Marquié M, Martinez-Lage P,… See abstract for full author list ➔ Jansen WJ, et al. Among authors: janssen o. JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216. JAMA Neurol. 2022. PMID: 35099509
Time from diagnosis to institutionalization and death in people with dementia.
Joling KJ, Janssen O, Francke AL, Verheij RA, Lissenberg-Witte BI, Visser PJ, van Hout HPJ. Joling KJ, et al. Among authors: janssen o. Alzheimers Dement. 2020 Apr;16(4):662-671. doi: 10.1002/alz.12063. Epub 2020 Feb 18. Alzheimers Dement. 2020. PMID: 32072728 Free PMC article.
Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer.
Hugendieck G, Lettau M, Andreas S, Neumann S, Reinhardt N, Arnold P, Theilig F, Bastian L, Rogmans C, Weimer JP, Flörkemeier I, Wesch D, Arnold N, Maass N, Janssen O, Bauerschlag D, Hedemann N. Hugendieck G, et al. Among authors: janssen o. J Extracell Vesicles. 2023 Jul;12(7):e12338. doi: 10.1002/jev2.12338. J Extracell Vesicles. 2023. PMID: 37408115 Free PMC article.
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Hellmold D, Kubelt C, Daunke T, Beckinger S, Janssen O, Hauck M, Schütt F, Adelung R, Lucius R, Haag J, Sebens S, Synowitz M, Held-Feindt J. Hellmold D, et al. Among authors: janssen o. Int J Mol Sci. 2023 May 22;24(10):9075. doi: 10.3390/ijms24109075. Int J Mol Sci. 2023. PMID: 37240419 Free PMC article.
263 results